Abstract
Drugs that target microtubules are a successful class of anti-cancer agents that have been in clinical use for over two decades. Acquired resistance to these drugs, however, remains a serious problem. Microtubule alterations, such as tubulin mutations and altered β- tubulin isotype expression, are prominent factors in development of resistance. Changes in actin and intermediate filament proteins can also mediate sensitivity to microtubule-targeting drugs. This review focuses on the mechanisms by which alterations in cytoskeletal proteins lead to drug resistance. This information will be helpful for improving the targeting of microtubule toxins.
Keywords: Actin, Cytoskeleton, Drug resistance, Intermediate filament, MDR, Microtubule, Microtubule-targeting drugs, C-terminal amino acids, Microfilaments, microtubule-destabilizers
Anti-Cancer Agents in Medicinal Chemistry
Title:Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics
Volume: 13 Issue: 1
Author(s): Arun Kanakkanthara, Paul H. Teesdale-Spittle and John H. Miller
Affiliation:
Keywords: Actin, Cytoskeleton, Drug resistance, Intermediate filament, MDR, Microtubule, Microtubule-targeting drugs, C-terminal amino acids, Microfilaments, microtubule-destabilizers
Abstract: Drugs that target microtubules are a successful class of anti-cancer agents that have been in clinical use for over two decades. Acquired resistance to these drugs, however, remains a serious problem. Microtubule alterations, such as tubulin mutations and altered β- tubulin isotype expression, are prominent factors in development of resistance. Changes in actin and intermediate filament proteins can also mediate sensitivity to microtubule-targeting drugs. This review focuses on the mechanisms by which alterations in cytoskeletal proteins lead to drug resistance. This information will be helpful for improving the targeting of microtubule toxins.
Export Options
About this article
Cite this article as:
Kanakkanthara Arun, H. Teesdale-Spittle Paul and H. Miller John, Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (1) . https://dx.doi.org/10.2174/1871520611307010147
DOI https://dx.doi.org/10.2174/1871520611307010147 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiosensitizing Effect of Electrochemotherapy: A Systematic Review of Protocols and Efficiency
Current Drug Targets Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
Current Pharmaceutical Design Natural Products Based Anticancer Agents
Mini-Reviews in Organic Chemistry Molecular Predictors of Efficacy to Anti-EGFR Agents in Colorectal Cancer Patients
Current Cancer Drug Targets New Strategies for Metabolic Support in Cancer
Current Nutrition & Food Science Specific Targeted Therapy: A New Tool for the Destruction of Cancer
Current Drug Therapy Recent Patents on Heat Shock Proteins Targeting Antibodies
Recent Patents on Anti-Cancer Drug Discovery Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Editorial [Hot Topic:Recent Advances in Molecular Targeting of Head and Neck Cancer (Guest Editor: Dong Moon Shin, M.D.)]
Current Cancer Drug Targets Recent Progress in Phosphoinositide 3-Kinases: Oncogenic Properties and Prognostic and Therapeutic Implications
Current Protein & Peptide Science Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions
Current Drug Metabolism Onconeural Versus Paraneoplastic Antigens?
Current Medicinal Chemistry SCYL1-BP1 Affects Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells via Cyclin F and RRM2
Anti-Cancer Agents in Medicinal Chemistry Pathology of the HPV-associated Oropharyngeal Carcinoma
Current Cancer Therapy Reviews Augmentation Therapy with Alpha1-antitrypsin: Novel Perspectives
Cardiovascular & Hematological Disorders-Drug Targets Natural Killer Cells Preferentially Target Cancer Stem Cells; Role of Monocytes in Protection Against NK Cell Mediated Lysis of Cancer Stem Cells
Current Drug Delivery Four Major Factors Regulate Phosphatidylinositol 3-kinase Signaling Pathway in Cancers Induced by Infection of Human Papillomaviruses
Current Medicinal Chemistry Hitting the Golden TORget: Curcumin’s Effects on mTOR Signaling
Anti-Cancer Agents in Medicinal Chemistry Perspectives on Adipose-Derived Stem/Stromal Cells as Potential Treatment for Scarred Vocal Folds: Opportunity and Challenges
Current Stem Cell Research & Therapy